Loading candles…
Syngene International Ltd., established in 1993 as a subsidiary of Biocon, operates as an integrated contract research, development, and manufacturing organization. It provides end-to-end drug discovery, development, and manufacturing services (CRAMS) on a single platform. The company caters to multiple industries including pharmaceuticals, biotechnology, nutrition, animal health, consumer goods, and specialty chemicals. Syngene offers a range of services such as drug discovery and development services, manufacturing services, and scientific services spanning the entire drug discovery and development value chain. Notably, it is recognized as India's first Contract Research Organization (CRO). The company supports global pharmaceutical and biotechnology firms as a strategic partner. Its research and manufacturing facilities cover approximately 1.9 million square feet and employ a workforce of over 5,600 scientists.
This page is a live market overview for SYNGENE INTERNATIONAL LTD (SYNGENE) on the NSE. As a listed security, SYNGENE INTERNATIONAL LTD is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for SYNGENE before placing trades on tick2trade.
As of the latest feed, SYNGENE last traded at ₹403.7 on NSE, up ₹3.95 (0.99%) from the previous close of ₹399.75. Today's session range is ₹397.85 – ₹412.2, against a 52-week band of ₹375.25 – ₹709.5. Traded volume today stands at 22.61L shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for SYNGENE in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether SYNGENE is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for SYNGENE INTERNATIONAL LTD before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in SYNGENE. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated SYNGENE option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 | 29 Jul 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 and dividend | 29 Apr 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 22 Jan 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 5 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 23 Jul 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and dividend | 23 Apr 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.